GlassScriptPhysician profile
Sunit P Kabaria
NPI 1134266240
$3,860.44
in general payments reported to CMS, 2019-2025
21 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $1,905 · 2021: $325 · 2022: $300 · 2023: $378 · 2024: $221 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.89 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,732.09 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $514.69 | 2019-2023 | Lokelma, Farxiga |
| Amgen INC. | $384.16 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Vifor Pharma, INC. | $351.42 | 2019-2023 | Veltassa |
| Fresenius USA Marketing, INC. | $156.70 | 2019-2023 | Velphoro, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $99.20 | 2021-2025 | |
| Glaxosmithkline, LLC. | $92.39 | 2022-2024 | Benlysta, Jesduvroq |
| Ardelyx, INC. | $78.91 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $57.82 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $53.91 | 2019-2020 | |
| Daiichi Sankyo INC. | $40.50 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $40.47 | 2022-2024 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $40.25 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $40.05 | 2021-2025 | Lupkynis |
| Akebia Therapeutics INC | $40.00 | 2019-2025 | Vafseo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $30.13 | 2025 | Tarpeyo |
| Amarin Pharma, INC. | $26.96 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $26.83 | 2020-2025 | Jynarque |
| Travere Therapeutics, INC. | $26.02 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $14.71 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunit Kabaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.